Insider Selling: Artivion (NYSE:AORT) CEO Sells $2,026,500.00 in Stock

Artivion, Inc. (NYSE:AORT) CEO James Mackin sold 70,000 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $28.95, for a total transaction of $2,026,500.00. Following the transaction, the chief executive officer directly owned 877,275 shares of the company’s stock, valued at approximately $25,397,111.25. This represents a 7.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Artivion Stock Down 2.8%

Shares of AORT traded down $0.82 during midday trading on Thursday, hitting $28.00. The company had a trading volume of 262,630 shares, compared to its average volume of 595,501. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of -399.94 and a beta of 1.25. The company’s 50 day moving average price is $24.77 and its 200 day moving average price is $30.24. The company has a quick ratio of 2.51, a current ratio of 3.47 and a debt-to-equity ratio of 0.82. Artivion, Inc. has a 52 week low of $19.16 and a 52 week high of $48.25.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.13 EPS for the quarter. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%.The business had revenue of $125.76 million during the quarter, compared to the consensus estimate of $119.99 million. On average, equities research analysts predict that Artivion, Inc. will post 0.45 EPS for the current year.

Institutional Trading of Artivion

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd bought a new stake in shares of Artivion in the 3rd quarter worth approximately $27,000. Rockefeller Capital Management L.P. boosted its position in Artivion by 150.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock valued at $30,000 after purchasing an additional 399 shares during the period. Larson Financial Group LLC grew its stake in Artivion by 148.5% during the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after buying an additional 563 shares during the last quarter. Smartleaf Asset Management LLC grew its stake in Artivion by 47.7% during the 2nd quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after buying an additional 538 shares during the last quarter. Finally, KBC Group NV acquired a new stake in Artivion in the fourth quarter worth $65,000. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Citigroup reissued a “market outperform” rating on shares of Artivion in a research report on Tuesday, July 21st. Wall Street Zen downgraded shares of Artivion from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Canaccord Genuity Group boosted their target price on shares of Artivion from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday. Stifel Nicolaus set a $45.00 target price on shares of Artivion in a report on Monday, June 1st. Finally, Citizens Jmp reduced their price target on shares of Artivion from $53.00 to $48.00 and set a “market outperform” rating on the stock in a research report on Friday, May 8th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Artivion has an average rating of “Moderate Buy” and an average price target of $44.83.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.